Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

NCT05425745 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT05425745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05425745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 3
Overall status
Completed
Start date
July 25, 2022
Completion date
May 28, 2024
Enrollment
354 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, familial hypercholesterolemia, genetic disease, inborn, high cholesterol, hypercholesterolemia, hyperlipoproteinemias, lipid metabolism disorder, lipid metabolism, inborn errors, metabolic disease